Tristel Gets FDA Approval for Ultrasound Disinfectant
By Elena Vardon
Tristel on Monday said its ULT high-level disinfectant has gotten approval by the U.S. Food and Drug Administration for its immediate sale for use on endocavity ultrasound probes and skin surface transducers.
The manufacturer of infection-prevention products said it will launch the product in the U.S. market in October. The group is working with Parker Laboratories and established a manufacturing base in New Jersey to make the disinfectant, which it will distribute using Parker's network for the ultrasound market.
Its DUO intermediate level disinfectant is now registered in all U.S. states, the London-listed group added.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
June 05, 2023 03:04 ET (07:04 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?